Journey Medical Corporati... (DERM)
The price, the headline numbers and the latest news, in one place.
Journey Medical Corporation (DERM) Stock Price, Analysis & Data
| Bid | 5.43 |
| Market Cap | 212.53M |
| Revenue (ttm) | 68.18M |
| Net Income (ttm) | -6.1M |
| 1.08 | |
| -0.22 | |
| n/a | |
| -125.5 | |
| P/B (ttm) | 6.49 |
| P/S (ttm) | 3.12 |
| Earnings Date | Nov 11, 2026 |
| Ask | 9.6 |
| Volume | 74,230 |
| Avg. Volume (20D) | 251,041 |
| Open | 7.58 |
| Previous Close | 7.54 |
| Day's Range | 7.47 - 7.82 |
| 52-Week Range | 4.31 - 9.55 |
| Analyst | Strong Buy |
| Price Target | 13.5 (79.28%) |
| Dividends | n/a |
| Ex-Dividend Date | n/a |
About DERM
Journey Medical Corporation, a commercial-stage pharmaceutical company that focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topica...
Financial Performance
In 2025, Journey Medical's revenue was 61.86M, an increase of 10.2% compared to the previous year's 56.13M. Earnings were -11.43M, a decrease of -22.09%.
Financial StatementsAnalyst Forecast
According to 4 analyst ratings, the average rating for DERM stock is "Strong Buy". The 12-month stock price forecast is 13.5, which is upside of 79.28% from the latest price.
Stock ForecastsEarnings Surprise
- Revenue of $15.96M misses estimates by $0, with 21.48% YoY growth.
- EPS of -0.01 exceeds estimates by 0.01, with 93.75% YoY growth.
Analysts project revenue of ... Upgrade
